Proposal relating to eltrombopag, zanamivir and various respiratory products
PHARMAC is seeking feedback on a proposal relating to a provisional agreement with GlaxoSmithKline for a number of products.
In summary, from 1 January 2014 the proposal would result in:
- The listing of eltrombopag (Revolade) in the community and hospital for the treatment of idiopathic thrombocytopenic purpura (ITP), under Special Authority criteria and hospital restrictions;
- The listing of zanamivir (Relenza Rotadisk) in the hospital for treatment and prophylaxis of influenza in hospitalised patients, subject to hospital restrictions;
- The removal of the Special Authority and hospital restrictions from fluticasone with salmeterol combination inhalers (Seretide and Seretide Accuhaler).
The proposal would also result in changes to the commercial arrangement for fluticasone (Flixotide and Flixotide Accuhaler), salmeterol (Serevent and Serevent Accuhaler) and fluticasone with salmeterol (Seretide and Seretide Accuhaler) although the listings of these products in the Pharmaceutical Schedule would not be affected and they would remain fully funded in the community.
PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by Friday, 15 November 2013 to:
Therapeutic Group Manager
Fax: 04 460 4995
Post: PO Box 10 254, Wellington 6143
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.